Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs

The recruitment status of this study is unknown because the information has not been verified recently.

Verified August 2008 by Imperial College London.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Imperial College London

ClinicalTrials.gov Identifier:

NCT00230672

First received: September 29, 2005

Last updated: August 12, 2008

Last verified: August 2008

History of Changes

Purpose

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels, including arteriovenous malformations in the lungs (PAVMs). We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of several proteins in the blood stream. We propose to take blood samples from patients at defined times in order to study changes in blood protein levels and activity

Condition
Telangiectasia, Hereditary Hemorrhagic


Study Type:	Observational
Study Design:	Time Perspective: Prospective
Official Title:	Studies of Plasma Proteins Derived From Pulmonary Arteriovenous Malformation Patients

Resource links provided by NLM:

Genetics Home Reference related topics: capillary malformation-arteriovenous malformation syndrome hereditary hemorrhagic telangiectasia Parkes Weber syndrome

MedlinePlus related topics: Arteriovenous Malformations

Genetic and Rare Diseases Information Center resources: Hereditary Hemorrhagic Telangiectasia Pulmonary Arteriovenous Malformation

U.S. FDA Resources

Further study details as provided by Imperial College London:


Estimated Enrollment:	70
Study Start Date:	March 2005

Eligibility


Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:Patients with hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations -

Exclusion Criteria:Unable to provide informed consent

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230672

Contacts


Contact: Claire Shovlin	0208 383 1000	c.shovlin@imperial.ac.uk

Locations


United Kingdom
Imperial College Hammersmith Campus	Recruiting
London, United Kingdom, W12 0NN
Contact: Claire Shovlin 0208 383 1000 c.shovlin@imperial.ac.uk

Sponsors and Collaborators

Imperial College London

Investigators


Principal Investigator:	Claire Shovlin	Imperial College London

More Information

No publications provided


ClinicalTrials.gov Identifier:	NCT00230672 History of Changes
Other Study ID Numbers:	IC/CLS7
Study First Received:	September 29, 2005
Last Updated:	August 12, 2008
Health Authority:	United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:


Arteriovenous Malformations Cardiovascular Abnormalities Congenital Abnormalities Vascular Malformations Telangiectasia, Hereditary Hemorrhagic Telangiectasis	Cardiovascular Diseases Hematologic Diseases Hemorrhagic Disorders Hemostatic Disorders Vascular Diseases

ClinicalTrials.gov processed this record on February 26, 2015

To Top